Aptose receives fast track designation for HM43239 in relapsed/refractory AML patients and FLT3 mutation

Aptose Biosciences

4 May 2022 - Aptose Biosciences today announced that the U.S. FDA has granted fast track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory acute myeloid leukaemia with FLT3 mutation. 

HM43239 received orphan drug designation from the FDA for treatment of acute myeloid leukaemia in 2018.

Read Aptose Biosciences press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track